Pruritus - Pipeline Review, H1 2018

  • ID: 4473087
  • Report
  • 134 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Amorepacific Corp
  • Celgene Corp
  • Hydra Biosciences Inc
  • RDD Pharma Ltd
  • Tioga Pharmaceuticals Inc
  • MORE
Pruritus - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2018, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 15, 3, 1 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Albireo Pharma Inc
  • Amorepacific Corp
  • Celgene Corp
  • Hydra Biosciences Inc
  • RDD Pharma Ltd
  • Tioga Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Pruritus - Overview

Pruritus - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pruritus - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pruritus - Companies Involved in Therapeutics Development

Albireo Pharma Inc

Allergan Plc

Amgen Inc

Amorepacific Corp

Asana BioSciences LLC

Cara Therapeutics Inc

Celgene Corp

Chugai Pharmaceutical Co Ltd

ELORAC Inc

GlaxoSmithKline Plc

Hydra Biosciences Inc

Japan Tobacco Inc

NeuroCycle Therapeutics GmbH

Patagonia Pharmaceuticals LLC

Patara Pharma Inc

RDD Pharma Ltd

Sanwa Kagaku Kenkyusho Co Ltd

Sienna Biopharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Teikoku Pharma USA Inc

Tesaro Inc

Tioga Pharmaceuticals Inc

Toray Industries Inc

Vanda Pharmaceuticals Inc

Pruritus - Drug Profiles

A-4250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-8379 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asimadoline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bepotastine besilate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

difelikefalin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2330672 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTS-661 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalbuphine hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalfurafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPK-88002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant maleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PATN-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Target TRPV1 for Pain and Itch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDD-1609 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-1405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize KOR1 for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPU-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tradipitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VVZ-149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pruritus - Dormant Projects

Pruritus - Discontinued Products

Pruritus - Product Development Milestones

Featured News & Press Releases

Feb 14, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-

Jan 31, 2018: Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

Nov 21, 2017: Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis

Oct 31, 2017: Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting

Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-

Oct 17, 2017: Cara Therapeutics Announces Participation in ANESTHESIOLOGY 2

Oct 17, 2017: Menlo Therapeutics Expands its Management Team

Oct 16, 2017: Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus

Oct 16, 2017: Cara Therapeutics to Present Data at Kidney Week 2

Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2

Sep 22, 2017: Toray Receives Japanese Approval for an Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5µg and REMITCH OD Tablets 2.5µg

Sep 18, 2017: Serlopitant Pruritus Reduction Results from Two Phase 2 Studies Presented at the 26th European Academy of Dermatology and Venereology

Sep 13, 2017: Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis

Aug 01, 2017: Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer

Jun 23, 2017: Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Pruritus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pruritus - Pipeline by Albireo Pharma Inc, H1 2018

Pruritus - Pipeline by Allergan Plc, H1 2018

Pruritus - Pipeline by Amgen Inc, H1 2018

Pruritus - Pipeline by Amorepacific Corp, H1 2018

Pruritus - Pipeline by Asana BioSciences LLC, H1 2018

Pruritus - Pipeline by Cara Therapeutics Inc, H1 2018

Pruritus - Pipeline by Celgene Corp, H1 2018

Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Pruritus - Pipeline by ELORAC Inc, H1 2018

Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2018

Pruritus - Pipeline by Hydra Biosciences Inc, H1 2018

Pruritus - Pipeline by Japan Tobacco Inc, H1 2018

Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H1 2018

Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1 2018

Pruritus - Pipeline by Patara Pharma Inc, H1 2018

Pruritus - Pipeline by RDD Pharma Ltd, H1 2018

Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018

Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, H1 2018

Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Pruritus - Pipeline by Teikoku Pharma USA Inc, H1 2018

Pruritus - Pipeline by Tesaro Inc, H1 2018

Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H1 2018

Pruritus - Pipeline by Toray Industries Inc, H1 2018

Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H1 2018

Pruritus - Dormant Projects, H1 2018

Pruritus - Dormant Projects, H1 2018 (Contd..1), H1 2018

Pruritus - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Pruritus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Albireo Pharma Inc
  • Allergan Plc
  • Amgen Inc
  • Amorepacific Corp
  • Asana BioSciences LLC
  • Cara Therapeutics Inc
  • Celgene Corp
  • Chugai Pharmaceutical Co Ltd
  • ELORAC Inc
  • GlaxoSmithKline Plc
  • Hydra Biosciences Inc
  • Japan Tobacco Inc
  • NeuroCycle Therapeutics GmbH
  • Patagonia Pharmaceuticals LLC
  • Patara Pharma Inc
  • RDD Pharma Ltd
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Sienna Biopharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Teikoku Pharma USA Inc
  • Tesaro Inc
  • Tioga Pharmaceuticals Inc
  • Toray Industries Inc
  • Vanda Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll